PLoS Pathogens, 2020 High-risk human papillomaviruses (HPVs) cause 5% of human cancers. Despite the availability of HPV vaccines, there remains a strong urgency to find ways to treat persistent HPV infections, as current HPV vaccines are not therapeutic for individuals ...
Wei Wang +9 more
doaj +1 more source
Prophylactic HPV vaccines [PDF]
Archive of Oncology, 2009 Human papillomavirus (HPV) is one of the most common sexually transmitted diseases worldwide. Cervical and other anogenital cancers, cervical and anal intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis are HPV associated ...
Mandić Aljoša
doaj +1 more source
Global challenges of implementing human papillomavirus vaccines
International Journal for Equity in Health, 2011 Human Papillomavirus vaccines are widely hailed as a sweeping pharmaceutical innovation for the universal benefit of all women. The implementation of the vaccines, however, is far from universal or equitable.
Mishra Amrita, Graham Janice E
doaj +1 more source
Novel Antigenic Targets of HPV Therapeutic Vaccines
Vaccines, 2021 Human papillomavirus (HPV) infection is the cause of the majority of cervical cancers and head and neck cancers worldwide. Although prophylactic vaccines and cervical cancer screening programs have shown efficacy in preventing HPV-associated cervical ...
Ditte Rahbæk Boilesen +2 more
doaj +1 more source
Human papillomavirus and HPV vaccines: a review [PDF]
, 2007 Cervical cancer, the most common cancer affecting women in developing countries, is caused by persistent infection with "high-risk" genotypes of human papillomaviruses (HPV). The most common oncogenic HPV genotypes are 16 and 18, causing approximately 70%
Castellsague, X. +10 more
core +3 more sources
Human papillomavirus vaccination coverage in Luxembourg : implications of lowering and restricting target age groups [PDF]
, 2018 Background: In Luxembourg, a national Human Papillomavirus (HPV) vaccination programme was introduced in 2008, targeting 12-17 year old girls offering a choice of bivalent or quadrivalent vaccine free of charge.
Arbyn, Marc +3 more
core +2 more sources
Evaluation of the burden of HPV-related hospitalizations as a useful tool to increase awareness: 2007–2017 data from the sicilian hospital discharge records [PDF]
, 2020 In light of the implementation of human papillomavirus (HPV) prevention strategies, epidemiological studies in different geographical areas are required in order to assess the impact of HPV-related diseases.
Amato L. +10 more
core +1 more source
Knowledge About the Human Papillomavirus Vaccine Among Employees at a Tertiary Cancer Center: Room for Improvement [PDF]
, 2020 Introduction: The human papillomavirus (HPV) vaccine is recommended by the U.S. Centers for Disease Control and Prevention for routine vaccination of boys and girls to protect against HPV-related cancers and genital warts. To meet the Healthy People 2020
Baum, George P +8 more
core +2 more sources
Using Intervention Mapping to Develop an Efficacious Multicomponent Systems-Based Intervention to Increase Human Papillomavirus (HPV) Vaccination in a Large Urban Pediatric Clinic Network [PDF]
, 2020 Background: The CDC recommends HPV vaccine for all adolescents to prevent cervical, anal, oropharyngeal, vaginal, vulvar, and penile cancers, and genital warts. HPV vaccine rates currently fall short of national vaccination goals.
Coan, Sharon P. +8 more
core +2 more sources
Detection and genotyping of human Papillomavirus in urine samples from unvaccinated male and female adolescents in Italy [PDF]
, 2013 The introduction of vaccination against Human Papillomavirus (HPV) in adolescent girls in 2006 has focused virological surveillance on this age group. As few studies have evaluated HPV infections in young populations, further data are needed in order to ...
Amicizia, Daniela +15 more
core +5 more sources